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Abstract 
Vaiana, Christopher A., M.S., Department of Biochemistry and Molecular Biology, 
Wright State University, 2010 
Bio-functionalized Clay Nanoparticles for Wound Healing Applications 
 
Wound healing is a complex, multi-step process that can be summarized 
into three stages, namely hemostasis and inflammation, proliferation, and finally 
tissue remodeling.  Battlefield wound healing demands rapid hemostasis using 
clotting or cauterizing agents to immediately limit blood loss, but this occurs at 
the expense of proper tissue repair beyond hemostasis.  Layered silicate clays 
such as kaolin and montmorillonite (MMT) have been previously shown to induce 
blood clotting due to their ability to form charged interactions with clotting factors.  
The charge characteristics of sodium MMT (Na-MMT) also enable 
functionalization with active biomolecules.  Herein we first functionalize three 
types of alumoinosilicate clays, namely Na-MMT, kaolin, and halloysite with 
horseradish peroxidase (HRP) as a model system with which to study the binding 
and biological activity of biomolecules bound to MMT.  We then functionalized 
Na-MMT with epidermal growth factor (EGF) via ion exchange reaction to create 
a nanocomposite (MMT-EGF) with EGF occupying approximately 0.12 % of the 
Na+ exchange sites and conduct biochemical analysis of keratinocytes after 
treatment with MMT-EGF.  Our results demonstrate that EGF immobilized on 
MMT retains the ability to activate the epidermal growth factor receptor (EGRF), 
causing phosphorylation of the AKT and MEK1 pathways, as well as upregulation 
of its downstream target gene expression involved in cell growth and migration.  
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This study also shows that like EGF, MMT-EGF treatment can stimulate cell 
migration in vitro, which is dependent on ERK1/2 phosphorylation. 
  
vi 
 
Table of Contents 
 
I. Introduction 
A. An overview of epidermal wound healing.  .  .  .  .  .  .  .  .  .  . .  .  1 
B. The structure and function of epidermal growth factor and its  
receptor.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 4 
C. The role of epidermal growth factor in wound healing.  .  .  .  .  .   5 
D. Structure and application of layered aluminosilicate clays.  .  .  .   6 
E. Enzymes and their use in aluminosilicate nanocomposites.  .  .  . 10 
F. Rationale and significance.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   11 
II. Materials and methods 
A. Materials.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   14 
B. Cell culture.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   14 
C. Preparation of enzyme-clay nano complexes via solution  
Mixing.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 15 
D. Preparation of MMT-EGF nano compleves via solution mixing.  . 16 
E. Characterization of composite nano complexes.  .  .  .  .  .  .  .  .   16 
F. Enzyme kinetics assay.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  20 
G. Cell proliferation assay.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   20 
H. Bright field and immunofluorescent imaging of IMR-90 cells 
post-MMT treatment.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 21 
I. Confocal immunofluorescence analysis of EGFR activation.  .  .  22 
J. Western blot analysis.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  22 
vii 
 
K. Wound closure assay.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 23 
L. Quantitative real-time RT-PCR analysis.  .  .  .  .  .  .  .  .  .  .  .  .   24 
III. Results 
A. Characterization of clay-enzyme complexes.  .  .  .  .  .  .  .  .  .  .  26 
B. MMT-HRP exhibits stabilized Michaelis-Menten kinetics.  .  .  .  . 32 
C. MMT, kaolin, and halloysite inhibit HaCaT and IMR-90 
proliferation in a dose dependent manner.  .  .  .  .  .  .  .  .  .  .  .   41 
D. Characterization of MMT-EGF complexes.  .  .  .  .  .  .  .  .  .  .  .   49 
E. Treatment of HaCaT cells with MMT-EGF leads to EGFR 
Activation.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 57 
F. MMT-EGF mediated increased cell migration of HaCaT is 
dependent on ERK activation.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 63 
IV. Discussion 
A. Bio-inorganic hybrid nanomaterials and their applications.  .  .  .  74 
B. Clay nanomaterials for drug delivery applications.  .  .  .  .  .  .  .   76 
C. Growth factor therapy for wound healing.  .  .  .  .  .  .  .  .  .  .  .  . 78 
V. References.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 83 
  
viii 
 
List of Figures 
 
Figure 1: Schematic representation of the cutaneous wound healing 
Process.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 3 
Figure 2: Schematic representation of EGFR inhibition of apoptosis via AKT 
and MEK.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   8 
Figure 3: Schematic representation of x-ray diffraction characterization of 
layered clay.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 19 
Figure 4: Western blot analysis of clay-horseradish peroxidase 
nanocomposites.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 28 
Figure 5: X-ray diffraction characterization of enzyme bound MMT.  .  .  .  . 31 
Figure 6: MMT-HRP exhibits stabilized Michaelis-Menten kinetics at varying 
pH .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   36 
Figure 7: Lineweaver-Burke plot of the activity of free HRP versus 
MMT-HRP .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   38 
Figure 8: Dose dependent survival of HaCaT cells upon treatment with 
increasing clay concentrations.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .43 
Figure 9: Dose dependent survival of IMR-90 cells upon treatment with 
increasing clay concentrations.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .46 
Figure 10: MMT clay particles adhere to the surface of IMR-90 cells and 
induce aggregation.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  48 
Figure 11: Characterization of MMT-EGF nanocomplexes.  .  .  .  .  .  .  .  .  . 51 
Figure 12: AFM analysis of MMT-EGF nanocomplexes.  .  .  .  .  .  .  .  .  .  .  54 
ix 
 
Figure 13: MMT-EGF is stable in cell culture media.  .  .  .  .  .  .  .  .  .  .  .  . 56 
Figure 14: Confocal microscopy analysis of EGFR activation.  .  .  .  .  .  .  .  60 
Figure 15: Activation of EGFR leads to AKT and ERK activation in HaCaT 
cells treated with MMT-EGF.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   62 
Figure 16: HaCaT migration in response to MMT-EGF treatment.  .  .  .  .  . 65 
Figure 17: IMR-90 migration in response to MMT-EGF treatment.  .  .  .  .  . 68 
Figure 18: Inhibition of MEK1 suppresses MMT-EGF induced cell 
Migration.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   70 
Figure 19: Expression of S100A2, VEGF, and THBS1 in response to 
MMT-EGF treatment.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   73 
Figure 20: Schematic diagram of hypothesized MMT-EGF induced growth 
signaling in HaCaTs.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 81 
 
  
x 
 
List of Tables 
Table 1: Enzyme kinetic values of free and MMT-immobilized HRP at pH 7 
and pH 4.5.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   40 
  
xi 
 
Acknowledgements 
I would like to express heartfelt gratitude toward my advisors Dr. Madhavi 
Kadakia and Dr. Rajesh Naik, whose unfaltering discipline, encouragement, and 
wisdom have made this work possible, and who have set for me a precedent of 
excellence and a true love of research, which I shall carry with me forever – 
thank you for all you have done. 
I would like to thank the members of the Kadakia lab past and present, especially 
Katie Leonard, Andy Whitlatch, and Ramma Kommagani, as well as the 
members of the Naik lab, especially Lawrence Drummy and Kristi Singh, for their 
contributions not only to this work, but to my growth as a person and researcher. 
I would like to thank Dr. Athanasios Bubulya and Dr. Richard Vaia for their 
sincere guidance throughout this project, and Dr. Lawrence Prochaska as a 
member of my thesis committee – thank you for making this effort possible. 
I would finally like to thank my parents, family, and friends whose love, support, 
patience, and encouragement have made me the person I am today. 
 
1 
 
I. Introduction 
A.  An overview of epidermal wound healing 
Skin is the largest organ in the human body, composed of an outer 
epidermis and inner dermis, and serves many functions including protection from 
the environment, fluid maintenance, and thermal regulation (Madison).  Because 
the epidermis is our body’s primary protection against the external environment, 
it is susceptible to frequent wounding, and therefore is equipped with a complex 
healing mechanism.  Wound healing is a multi-staged cellular response, resulting 
in the activation of several overlapping cascades of protein activity (Martin).  The 
different stages of wound healing can be classified as: hemostasis and 
inflammation, proliferation, and tissue remodeling as depicted in Figure 1 
(Stadelmann, Digenis and Tobin; Beanes et al.).  Hemostasis (blood clotting) is 
the body’s immediate response to limiting blood and fluid loss by sealing the 
wound shut.  During this stage, vasoconstriction and platelet aggregation begin 
clotting, followed by the activation of several events making up the coagulation 
cascade.  The release of growth factors initiates the proliferative stage, where 
angiogenesis, collagen scaffold formation, fibroplasia, and epithelialization occur 
(Singer and Clark).  This proliferation stage begins within hours of hemostasis, 
and may last weeks to months depending on the severity of the wound (Beanes 
et al.).  Finally the process ends with tissue remodeling which may take years to 
fully complete.  Because of the inherent complexity of wound healing, it is difficult 
to design new technologies that can enhance more than one stage of the healing 
process.   
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Figure 1. Schematic representation of the cutaneous wound healing 
process.  After injury, stage 1 of the wound healing process is the 
aggregation of platelets and activation of the coagulation cascade, resulting in 
the formation of a fibrin clot.  The release of growth factors initiates stage 2 
where a collagen scaffold is laid down and fibroblast proliferation across the 
wound area occurs.  The final stage, tissue remodeling, completes the 
process as reorganization of the new tissue takes place. 
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B.  The structure and function of epidermal growth factor and its receptor. 
 Epidermal growth factor (EGF) is a single-chain, 53 amino acid residue 
peptide involved in the regulation of cell proliferation and differentiation via the 
EGF receptor (EGFR) (Ogiso et al.).  EGF is one of several ligands that activate 
members of the ErbB receptor family, which includes EGFR (or ErbB1), ErbB2 
ErbB3, and ErbB4 (Danielsen and Maihle).  These membrane-spanning 
receptors, which are made up of an extracellular ligand-binding region, a trans-
membrane region, and an intracellular region, have been shown to play a role in 
the regulation of cell replication, movement, and survival.  The extracellular 
region of EGFR consist of 4 domains (I – IV) with EGF docking between domains 
I and III (Ogiso et al.).  While it is known that activation of EGFR involves 
dimerization of two inactive EGFR monomers due to the docking of two EGF 
molecules, the exact mechanism by which this occurs is not completely known.  
Three distinct hypotheses exist to explain this mechanism; one hypothesis 
suggests ligand (EGF) dimerization facilitates the dimerization of the receptors, 
supported by the observation of the interaction between two asymmetric EGF 
molecules in X-ray crystallography; a second hypothesis suggests a receptor-
mediated mechanism, where the binding of EGF to EGFR induces a 
conformational change in EGFR that allows dimerization of two EGFR monomers; 
and a third hypothesis suggests a bivalent interaction between a single EGF 
molecule and two EGFR monomers (Lemmon et al.; Lu et al.; Ogiso et al.).  The 
dynamics of EGF-EGFR interaction may play an important role in designing 
different EGF-based delivery mechanisms for wound healing applications. 
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C. The role of epidermal growth factor in wound healing 
EGF is one of the major growth factors that stimulate cell proliferation and 
motility during tissue regeneration (Hudson and McCawley; Koivisto et al.; Liang 
et al.).  The use of EGF and other growth factors to stimulate cell proliferation 
during wound healing has been repeatedly demonstrated with varying success 
(Choi, Leong and Yoo; Fu et al.).  EGF acts by binding and activating EGFR, 
thereby communicating growth signals through various protein cascades 
(Langlands, Down and Kealey; Marques et al.).  One major pathway starts with 
phosphoinositide 3-kinase (PI3K).  Phosphorylation of PI3K by activated EGFR 
subsequently leads to activation of AKT pathway, a major conduit of PI3K pro-
growth signals (Hennessy et al.).  AKT activation leads to phopshorylation of 
several downstream targets which promote cell survival. For example, AKT 
phosphorylates and activates mammalian target of rapamycin (mTOR) which 
leads to translation of growth proteins such as p-70 (S6 kinase) and 
phosphorylation of S6 (Vander Haar et al.).  AKT also directly inhibits glycogen 
synthase kinase 3β (GSK3β) through phosphorylation, thereby inhibiting the 
degradation of β-catenin, resulting in transcription of c-JUN and other pro-growth 
genes (Jope and Johnson).  EGFR also promotes cell growth by means of 
mitogen activated protein kinase (MAPK) pathways such as ERK1/2 via the RAS-
RAF-MEK cascade (Seger and Krebs).  Interestingly, ERK activation has been 
shown to play a major role in epithelial cell migration during wound healing 
(Sharma, He and Bazan; Matsubayashi et al.).  Overexpression of EGFR and 
other ErbB receptors play a major role in some cancers, and have been shown to 
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promote their survival by suppression of apoptosis via PI3K/AKT/Bad or 
MAPK/RSKS/Bad interactions as depicted in Figure 2 (Danielsen and Maihle; 
Bose et al.). 
 Research in the use of growth factors for treatment of different types of 
wounds has gained momentum over the last several years.  Within the last 
decade or so, several growth factors including EGF, basic fibroblast growth factor 
(bFGF), and platelet-derived growth factor (PDGF) have gained United States 
FDA approval for wound healing (Fu et al.).  Healing of chronic wounds shows 
significant improvement with growth factor treatment, although several 
challenges still exist, such as the tendency of proteases activity in the wound 
area to destroy much of the growth factors upon treatment (Hardwicke et al.). 
D.  Structure and applications of layered aluminosilicate clays 
Aluminosilicates are abundant, natural, layered clay mineral structures 
composed predominantly of silicon, aluminum, and oxygen (Grim).  Nanoscale 
layered aluminosilicates have gained momentum in advanced biomedical uses 
such as cell scaffolding and drug delivery (G. V. Joshi et al.; S.R. Levis and P.B. 
Deasy; Mehta et al.; Aguzzi et al.). Montmorillonite (MMT) is an aluminosilicate 
clay mineral consisting of a 2:1 structure of two outer tetrahedral silicon layers 
sandwiching an inner octahedral aluminum layer.  MMT consists of a lamellar 
stack of crystalline, 1 nm thick aluminosilicate sheets.   
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Figure 2.  Schematic representation of EGFR inhibition of apoptosis via 
AKT and MEK.  Upon ligand binding, EGFR acts to phosphorylate and 
activate AKT via PI3-K and RSKS via the RAS-RAF-MEK signaling cascades.  
Active AKT and RSKS directly inhibit the apoptotic actions of Bad, thereby 
promoting cell survival. 
8 
 
 
9 
 
Naturally occurring cations (ie, Na+) reside between the sheets to balance the 
overall negative surface charge of the MMT.  In water, the lamellar stack swells 
producing an electrostatically stabilized dispersion of nanoscale sheets. Ingestion 
of MMT has been used therapeutically for the absorption of toxins in the colon 
and intestines (Aguzzi et al.).  The ion exchange capacity of MMT enables 
replacement of Na+ with other organic and inorganic cations to add functionality, 
spurring research into the use of MMT and other clay species as oral drug 
delivery agents for molecules such as 5-fluorouracil, a chemotherapeutic agent 
for treating colon cancer (Lin et al.). 
Kaolin is another aluminosilicate clay, consisting of a 1:1 structure of a 
single tetrahedral silicon layer and a single octahedral aluminum layer, that has 
been shown for years to induce coagulation by activating clotting factor such as 
Hageman Factor (Factor XII) (Cochrane, Revak and Wuepper).  It can be found 
in several ingested medicines as an antacid, and is used to mitigate diarrhea 
(Wald; Linare, Afonso and Rose-Brussin).  Halloysite is an aluminosilicate clay 
with a similar chemical makeup of kaolin, but is oriented in a hollow nano tubular 
structure as opposed to the lamellar stacks of MMT or kaolin.  Entrapment of 
drug molecules inside the tube for sustained drug release applications has been 
shown in several studies both in vitro and in vivo (S.R. Levis and P.B. Deasy; 
Price, Gaber and Lvov).  While the functionalization of MMT with drug molecules 
utilizes the clay’s ion exchange ability, drug loading of halloysite involves 
replacement of the intercalated water inside the hollow tube structure with a 
solution containing the molecule of choice.  MMT, kaolin, and halloysite each 
10 
 
have unique properties that make them attractive for use in the biomedical 
community.  Overall, the ion exchange nature, intercalation properties, and 
biocompatibility of clays make them ideal candidates for growth factor delivery. 
E.  Enzymes and their use in aluminosilicate nanocomposites. 
The interest in immobilization of enzymes and other active biomolecules 
onto clay surfaces for use as biocatalysts ranges from basic research to industry.  
The isolation and immobilization of enzymes that perform a desired reaction or 
yield a certain product has been used in industries such as food technology, 
biotechnology, biomedicine, and analytical chemistry (Gopinath and Sugunan; 
Hartmeier).  Common enzymes that have shown varying degrees of activity when 
immobilized include horseradish peroxidase (HRP) and glucose oxidase (GOX), 
among others (Lozzi et al.; Sanjay and Sugunan; Garwood, Mortland and 
Pinnavaia).  In some cases, research groups observe a decrease in the activity 
of enzymes immobilized to clay surfaces (Lozzi et al.).  Since the enzyme is 
being taken out of its natural environment, there are many external factors that 
may inhibit its activity such as temperature and ionic conditions.  Other research 
groups, however, show an increase or stabilization in activity of immobilized 
enzymes (Sanjay and Sugunan).  Enzymes function in a very crowded in vivo 
environment, and the confinement of enzymes in some porus materials has been 
reported to play a role in increasing enzyme activity (Dunker and Fernández).  
HRP is an example of a well-studied enzyme, and has been used in various 
applications in research, industry, and medicine today (Veitch).  It was used in 
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this study as a model with which to study the biological activity of clay-bound 
biomolecules in an aqueous environment. 
F.  Rationale and Significance. 
Research into the mechanisms behind each stage of wound healing and 
how to improve them is very active, with particular interest in the development of 
materials to enhance various stages of the wound healing process.  The military 
for example has a great interest in the development of improved hemostatic 
agents, since controlling blood loss during battlefield wounding continues to be a 
challenge (Alam et al.)  Many new technologies designed for rapid blood clotting 
on the front line involve supplementing the wound with natural or synthetic 
clotting factors, or cauterizing agents (Clay, Grayson and Zierold; Ellis-Behnke et 
al.).  Although cauterizing minerals like QuikClotTM are very fast and effective, 
they release a large amount of heat, posing a risk of burn and tissue damage to 
the patient or responder (Arnaud et al.)  In parallel, military and civilian wound 
care communities have pursued the use of new material solutions for improved 
cell proliferation beyond the hemostasis stage, such as the control of cellular 
growth and differentiation using bio-degradable silk fibroin scaffolds (Gupta et al.; 
Zhang, Baughman and Kaplan).  Modification of silk fibroin films with inorganic 
clay materials has shown increased mechanical properties while maintaining 
biocompatibility (Kharlampieva et al.).  Charged clay materials have been known 
for years to activate clotting factors, and certain layered clay species have 
demonstrated induction of coagulation at clotting times comparable to 
QuickClot™ without the release of heat (Baker et al.).  Wound care specialists 
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focusing on the proper restoration of the skin’s function after wounding are 
developing new epithelialization technologies such as skin grafts and improved 
vascularization (Simman, Craft and McKinney).  Plastic surgeons are making 
advances in tissue remodeling techniques and topical applications to reduce 
scarring and improve the long term aesthetics of tissue remodeling following 
wound healing (van den Helder and Hage).  Overall, modern research has 
gained much ground in producing technologies to advances individual stages of 
the wound healing process. 
Herein we propose the hypothesis that clay-immobilized growth factor will 
effectively activate pro-growth cellular signaling for wound healing applications, 
which we have tested with three specific aims.  First we study the intercalation 
efficiency and enzyme activity of HRP immobilized onto the surface of three 
aluminosilicate clays: MMT, kaolin, and halloysite.  These clays each have 
certain features that make them suitable options for biomedical uses as 
described above.  Second, we further select the clay with high binding 
efficiencies and enzyme activity, as well as a safe dosage of clay that produces 
no significant cell death in vitro, leading us to focus on the layered aluminosilicate 
clay MMT as a delivery mechanism for EGF.  Third, we verify the functionality of 
EGF immobilized on Na-MMT by focusing on the activation of the AKT and 
mitogen activated protein kinase (MEK1) mediated pathways and their 
downstream effector molecules.  We further confirmed that the spontaneously 
transformed keratinocyte cell line HaCaT, when treated with MMT-EGF, showed 
13 
 
increased migratory response dependent on activation of ERK1/2, a similar 
response to that of cells treated with EGF alone. 
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II. Materials and Methods 
A. Materials. 
Cloisite Na+ (92.6 meq/100 g), a refined and purified naturally occurring 
sodium montmorillonite (Na-MMT), was purchased from Southern Clay Products, 
Inc. (Gonzales, TX).  Kaolin and Halloysite nanoclay were purchased from 
Aldrich (St. Louis, MO).  Horseradish peroxidase (HRP) was purchased as a 
lyophilized powder from Sigma (St. Louis, MO) and reconstituted at 5 mg/ml in 
100 mM monopotassium phosphate buffer at pH 7.  Glucose oxidase (GOX) was 
purchased as a lyophilized powder from Sigma and reconstituted at 1 mg/ml in 
100 mM sodium acetate.  2,2’-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) 
diammonium salt (ABTS) was purchased as a lyophilized powder from Sigma 
and reconstituted in dH2O at pH 7 for immediate use.  Human Recombinant 
Epidermal Growth Factor (hr-EGF) was purchased as a lyophilized powder from 
R&D Systems Inc. (Minneapolis, MN) and reconstituted at 100 µg/ml in 10 mM 
acetic acid.  PD98059 (MEK1 inhibitor) was purchased from Cell Signaling 
Technologies (Beverly, MA) as a lyophilized powder and reconstituted at 20 mM 
in DMSO.   Rapamycin (mTor inhibitor) was purchased from Calbiochem (San 
Diego, CA) and reconstituted at 10 mM in Ethanol. 
 
B. Cell Culture. 
Human spontaneously transformed keratinocyte cell line HaCaT was 
generously provided by Dr. Dori Germolec from the National Institute of 
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Environmental Health Sciences and were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) with 8 % fetal bovine calf serum (FBS) and 100 U 
penicillin and 100 µg streptomycin (1 % PS).  Human primary fibroblast cell line 
IMR-90 was obtained from American Type Culture Collection (Manassas, VA), 
and were maintained in DMEM with 8 % FBS and 1 % PS. 
C. Preparation of enzyme-clay nano complexes via solution mixing. 
MMT, kaolin, or halloysite was added to de-ionized H2O (dH2O, pH 7) at a 
concentration of 10 mg/mL (1 % w/v) and vigorously stirred at room temperature 
for 48 hr with a magnetic stir bar, with MMT resulting in a yellow suspension and 
kaolin or halloysite resulting in a milky white suspension, which was autoclaved 
and stored at room temperature.  Clay (1 mg) was washed with 1 mL of dH2O 
(pH 7) and re-suspended in a total volume of 100 mL dH2O.  Reconstituted HRP 
(0.23 mg) was added to 15, 30, and 45 µl of the MMT, kaolin, or halloysite 
suspension, and the sample was brought up to a total volume of 1 mL of dH2O.  
The samples were rotated overnight at 4 ˚C, washed 5X with phosphate buffer 
(pH 7), and re-suspended in 100 µl dH2O.  The supernatants were collected for 
immunoblot assay, and the clay-HRP suspension was used immediately for all 
experiments.  Reconstituted GOX (1 mg) was added to 45 µl of the MMT 
suspension, then rotated overnight, washed 5 X with dH2O, and prepared for X-
ray diffraction characterization as described below. 
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D. Preparation of MMT-EGF nano complexes via solution mixing. 
MMT (1 mg) was washed twice by manually re-suspending with 1 ml of 
dH2O, pelleting, and discarding the supernatant, and the final pellet was re-
suspended in a total volume of 100 µL dH2O.  EGF was bound to MMT by adding 
50, 100, 250, or 500 ng of EGF, reconstituted in acetic acid, to 10 µl of the MMT 
suspension, and the sample was brought up to a total volume of 1 mL with dH2O.  
The samples were rotated for 12 hr at 4 ˚C, washed 2X with dH2O, and re-
suspended in 100 µL dH2O.  The supernatants were collected to assay for EGF 
using immunoblot analysis, and the EGF-MMT suspension was used 
immediately for all experiments.  For EGF desorption studies, 250 ng of 
reconstituted EGF was added to 10 µl of the MMT suspension, and the sample 
was brought up to a total volume of 1 ml culture media.  The suspension was 
incubated at 37 ˚C and 5 % CO2 for 72 hr.  At 24 hr time points, the samples 
were pelleted and washed 2X with dH2O, and the pellet and supernatant were 
collected for immuboblot assay. 
E. Characterization of composite nano complexes. 
MMT and MMT-enzyme samples were air-dried at room temperature onto 
glass coverslips into a powder and characterized by transmission X-ray 
diffraction (XRD).  MMT and MMT-EGF nano complexes were lyophilized into a 
powder and characterized by XRD.  A Rigaku rotating anode source (Cu-Kα), 
Statton camera and imaging plate detectors were used for data collection.  X-
Rays with a wavelength of 1.54 Å were used at distances of 53 mm and 175 mm 
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from the sample and data obtained was analyzed using the Fit2D software 
package (Andrew Hammersly, European Synchrotron Radiation Facility, 
Grenoble, France).  A schematic of the experimental setup and associated 
values is depicted in Figure 3.  The layer spacing was calculated using Bragg’s 
Law,  
           
and plotted against the scattering angle    or the scattering vector q which can 
be defined as 
          (  ⁄ ) 
with   being the wavelength of the incident X-ray beam (1.54 Å),   being the 
Bragg’s scattering angle,   being the spacing between clay sheets, and   being 
an integer (in this case   = 1) (Ganguly, Bhowmick and Li).  To analyze the 
surface topology and height of MMT and MMT-EGF, Atomic Force Microscopy 
(AFM) was performed using a Nanolink DPN 5000 Instrument equipped with a 
Pacific Nanotechnology closed-loop XYZ scanner.  Pre-mounted close contact 
probes from Pacific Nanotechnology were used for imaging in close contact 
mode.  The presence of EGF in MMT-EGF nano complexes was confirmed via 
immunoblot analysis as described below.  
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Figure 3.  Schematic representation of x-ray diffraction characterization 
of layered clay.  X-rays with a wavelength (λ) of 1.54 nm are diffracted off of 
the crystalline layers of the clay sample.  The intensity of the diffraction is 
detected and plotted against the scattering angle 2θ.  Using Bragg’s equation, 
the interlayer spacing distance d can be calculated. 
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F. Enzyme kinetics assay. 
Reconstituted HRP (1 mg, pH 7) was added to 4.5 mg of MMT in a total 
volume of 1 ml dH2O.  The samples were rotated overnight at 4˚C and split into 
two 500 µl aliquots, then each was washed 5X with buffer of varying pH (4.5 or 7).  
The samples were reconstituted in 1 mL buffer of varying pH and rotated for 1 hr 
at 4 ˚C, then washed 3X and re-suspended in 1 ml buffer.  Fractions (100 µl) of 
the final suspension were added to 100 µl ABTS of increasing concentrations 
and 30 µl of 0.003 % H2O2 in a 96-well plate, and the absorbance at 405 nm was 
measured at 11 second kinetic intervals using a Tecan Safire-2 plate reader and 
analyzed using the Magellan software package (Tecan).  Reconstituted HRP 
(100 ng) was included under the same conditions as a positive control.  The raw 
data was plotted as time (seconds) versus absorbance intensity for each 
substrate concentration (S), and the initial reaction velocity (V) was calculated 
from the slope using a linear fit trend line.  The final results were analyzed using 
the SigmaPlot software package as a non-linear regression of the plot of V 
versus S. 
G. Cell proliferation assay. 
Cells were plated at a density of 2.5 × 105 cells/well (HaCaT) or 5 × 104 
cells/well (IMR-90) in a six-well plate, and incubated at 37 ˚C and 5 % CO2.  MMT 
(1 % w/v) diluted to 0.1 %, 0.05%, 0.01 %, and 0.001 % in dH2O in a total volume 
of 2 ml was washed 2X with dH2O and 2X with DMEM, and resuspended in 2 ml 
of fresh DMEM.  At 24 hr post-plating of cells, the normal culture media was 
replaced with complete DMEM containing MMT of the aforementioned 
21 
 
concentrations.  Cells were harvested at 0, 24 and 48 hr post-treatment, stained 
with trypan blue and manually counted.  A separate culture well was used for 
each time point measurement.  The 0 hr time point contained no MMT, and was 
used to establish a baseline plating density for all conditions. 
H. Bright field and immunoflorescent imaging of IMR-90 cells post-MMT 
treatment. 
For bright field imaging, IMR-90 cells were plated at a density of 5 × 105 
cells/well in a six-well plate.  At 24 hr after seeding, cells were treated with 
increasing concentrations of MMT for 24 hr, then washed 3X with sterile PBS and 
imaged using a Leica DMI-6000B microscope.  For immunofluorescence staining, 
IMR-90 cells were plated on sterilized coverslips at a density of 5 × 105 cells/well 
in a six-well plate.  Cells were fixed with 2 % paraformaldehyde for 15 min 
followed by permeabilization  with 0.2 % Triton X-100 for 5 min. Cells were 
blocked with 0.5 % normal goat serum (NGS) and incubated with primary 
antibody against α-tubulin (1:4,000 dilution) for 1hr at room temperature.  After 
three washes with 0.5 % NGS, cells were incubated with secondary goat anti-
mouse, Texas-red conjugated antibody (1:500 dilution) (Jackson 
Immunoresearch, West Grove, PA).  VectaShield DAPI-containing fixing solution 
was used for nuclear staining.  A Leica DMI-6000B microscope was used for 
imaging of the samples. 
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I. Confocal immunofluorescence analysis of EGFR activation. 
HaCaT cells were plated on sterilized glass coverslips at a density of 2.5 × 
105 cells/well in a six-well plate.  At 24 hr after seeding, cells were serum starved 
for 24 hr followed by treatment with EGF or MMT-EGF for 30 min. For 
immunofluorescence staining, cells were fixed with 2 % paraformaldehyde for 15 
min followed by permeabilization  with 0.2 % Triton X-100 for 5 min. Cells were 
blocked with 0.5 % normal goat serum (NGS) and incubated with primary 
antibody against phospho-EGFR (1:1500 dilution) for 1 hr at room temperature.  
After three washes with 0.5 % NGS, cells were incubated with secondary goat 
anti-rabbit, fluorescein isothiocyanate (FITC)-conjugated antibody (1:500 dilution) 
(Invitrogen, Carlsbad, CA).  VectaShield DAPI-containing fixing solution was 
used for nuclear staining.  A Zeiss LSM-700 microscope was used for confocal 
imaging of the samples (Carl Zeiss MicroImaging, LLC, Thornwood, NY). 
J. Western blot analysis. 
HRP immobilization on MMT, kaolin, and halloysite was confirmed by 
fractioning clay pellets or supernatants onto a 7 % SDS polyacrylamide gel 
electrophoresis (PAGE).  Densitometry analysis was conducted using the 
Multigauge software package (Fuji).  EGF immobilization on MMT was confirmed 
by fractionating clay pellets or supernatant onto a 15 % SDS polyacrylamide gel.  
HaCaT cells treated with EGF or MMT-EGF in presence or absence of pre-
treatment with PD98059 (MEK1 inhibitor) or Rapamycin (mTOR inhibitor) were 
harvested and whole cell extracts were prepared by lysing the cells in 
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phosphatase inhibitors containing buffer (50 mM Tris-HCl pH 8, 120 mM NaCl, 5 
mM NaPPi, 10 mM NaF, 30 mM paranitrophenylphosphate, 1 mM benzamidine, 
0.1 % NP-40, 1 % Triton X-100 and 0.2 mM PMSF, 100 nM sodium 
orthovanadate) supplemented with protease inhibitors.  Equivalent amount of 
these whole cell extracts were run on a 10 % SDS PAGE. Samples were then 
transferred to a PVDF membrane and the membrane was blocked using 1 % 
BSA in tris-tween buffered saline (TTBS) for phosophorylated proteins or 5 % 
nonfat milk in TTBS for non-phosphorylated proteins.  Membranes were then 
probed with antibodies overnight at 4 °C that were specific for HRP (Abcam, 
Cambridge, MA), EGF (Sigma, St Louis, MO), total and phosphorylated AKT, 
GSK3β, S6, and ERK (Cell Signaling Technologies, Danvers, MA),  
phosphorylated EGFR (Cell Signaling Technologies), and finally β-actin (Sigma, 
St Louis, MO) which was used as a loading control.  Appropriate secondary 
HRP-conjugated antibodies for immunoblotting were obtained from Promega 
(Madison, WI), and used to probe the membranes for 1 hr at room temperature.  
The membranes were developed using chemiluminescence as previously 
described (Kommagani et al.).   
K. Wound closure assay. 
In vitro scratch-wound closure assay was used to measure the migration 
of cells after treatment with EGF-MMT (Zeineldin and Hudson).  Cells were 
plated at a density of 4 x 105 cells/well (HaCaT) or 5 x 105 cells/well (IMR-90) in a 
six-well plate and cultured in complete DMEM to near confluence.  The cells 
were then serum starved for 24 hr following which each well was manually 
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scratched with a micro-pipet to create two parallel vertical scratches and one 
perpendicular horizontal scratch, creating two intersections used as points of 
reference, and washed 3X with sterile PBS to remove cell debris.  The cells were 
then treated with EGF, MMT, or EGF-MMT equilibrated in serum-free DMEM 
were added at a concentration of 5 ng/mL EGF (growth factor concentration in 
EGF-MMT was estimated based on the loading conditions of 25 ng EGF/1 µg 
MMT).  Percentage of wound closure after t hours was observed by bright-field 
microscopy at 100X magnification, and quantified using the formula 
(
                          
            
)      
Images were taken at the vertical portions of the two scratch intersections 
yielding four total frames.  Reported data are the averages and standard 
deviations from at least three frames during a single representative experiment.  
The experiment was repeated 3 times yielding similar trends. The scratch-wound 
assay was repeated using HaCaTs with an additional 4 hr pre-treatment with 
rapamycin (RAPA) or PD98059 inhibitors prior to treatment with EGF or EGF-
MMT.  A control sample was pre-treated for 5 hr with DMSO vehicle.   
L. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis. 
HaCaT cells were plated at a density of 2.5x105 cells/well in a six well 
plate.  After 24 hr of seeding, the cells were serum starved for 24 hr, pretreated 
for 2 hr with 100 nM RAPA or 75 µM PD98059 followed by treatment with serum 
free DMEM supplemented with 5 ng/mL EGF or 0.001 % MMT-EGF.  At 1 hr 
post-treatment total RNA from cells was extracted using eZNA RNA isolation kit 
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(Omega Bio-tex, Norcross, GA) according to manufacturer’s protocol.  A total of 1 
µg RNA was used to synthesize cDNA by using TaqMan reverse transcription kit 
(Applied Biosystems, Foster City, CA).  TaqMan based real-time PCR analysis 
was performed in a 96 well microtiter plate format on an ABI Prism7900HT 
sequence detection system using TaqMan 2X master mix and gene specific 
assays on demand, and normalized to endogenous GAPDH endogenous control 
(part # 4326317E) (PE Applied Biosystems, Foster City, CA).  Assays on 
demand (AOD) were used for S100A2 (Hs_00195582_m1), VEGF 
(Hs_00900054_m1), and THBS1 (Hs_00170236_m1) (Applied Biosystems, 
Foster City, CA).   Relative mRNA quantitation was performed using the 
comparative Ct method (Pfaffl). 
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III. Results. 
A. Characterization of clay-enzyme complexes. 
Immunoblot analysis (western blot) is a commonly used technique to 
identify and quantify proteins based on antibody affinity for a specific amino acid 
sequence (Burnette).  Here, we used immunoblot analysis to confirm 
immobilization of HRP to the clay surface and measure the binding capacity to 
MMT, kaolin, or halloysite via comparative densitometry of the resulting bands.  
To prepare the clay-HRP samples for analysis, 15, 30, and 45 µl of 1 wt % MMT, 
kaolin, or halloysite were incubated with 0.23 mg HRP in a final volume of 1 ml in 
dH2O, and rotated overnight at 4 ˚C.  The clay was pelleted, and fractions of the 
pellet were subject to immunoblot analysis using HRP-specific antibodies.  As 
shown in Figure 4A, we demonstrated binding of HRP to MMT only, with little to 
no binding to kaolin and halloysite.  This is expected due to the strong surface 
charge and ion exchange capacity of Na-MMT (Lozzi et al.).  To quantitate the 
amount of HRP bound to MMT surface, we compared the band intensity of the 
MMT-HRP fractions containing unknown amounts of HRP, to a series of known 
HRP concentrations.  As seen in Figure 4B, a concentration dependent increase 
in HRP binding is observed in the MMT pellet with increasing concentrations of 
MMT.  By comparing the densities of unknown HRP concentrations in the pellet 
to the standard curve, we can calculate the binding capacity to be 0.070 (± 0.006) 
ng of HRP per 1 µg MMT.  This value was used to estimate the amount of HRP 
enzyme in our MMT-HRP pellet for future studies such as enzyme kinetics. 
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Figure 4.  Western blot analysis of clay-horseradish peroxidase 
nanocomposites.  A.  Immunoblot analysis of increasing amounts of MMT, 
kaolin (K), or Halloysite (H) incubated with an excess of HRP.  Pellet fractions 
were resolved on a 10 % SDS-PAGE and probed with anti-HRP.  HRP 
standards were also subject to immunoblot analysis.  B.  Density of the MMT-
HRP pellet was plotted against a linearly fit HRP standard curve. 
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MMT-HRP was further characterized by powder x-ray diffraction (XRD), a 
technique commonly used to analyze the change in lattice spacing of layered 
materials such as clay sheets occurring as a result of intercalation with different 
molecular species (Sanjay and Sugunan).  A second enzyme glucose oxidase 
(GOX), known to intercalate into Na-MMT, was also examined for comparison 
(Garwood, Mortland and Pinnavaia).  MMT (45 µl of 0.1 % w/v) was incubated 
with a solution of HRP or GOX as previously described.  Fractions of the sample 
were dried into a powder and subject to XRD analysis.  The diffraction intensity 
plotted against the scattering vector q in Figure 5 shows a shift in the peak 
representing basal layer spacing due to intercalation of HRP or GOX.  The 
structure of recombinant HRP has been determined by XRD to measure 
approximately 5 nm x 3.7 nm, corresponding to an estimated increase in layer 
spacing of 3 nm as indicated by Figure 5 after accounting for dehydration and 
sample preparation (Berglund et al.).  It can be hypothesized from this that the 
globular structure of HRP is conserved as it binds to MMT.  In contrast, the 
structure GOX is known through crystallography to measure approximately 6.7 
nm x 4.8 nm, while the diffraction pattern of MMT-GOX instead reflects a spacing 
change of 0.8 nm and 3.9 nm.  This is likely due to denaturation of GOX upon 
intercalation within MMT sheets which has been previously observed (Garwood, 
Mortland and Pinnavaia). 
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Figure 5.  X-ray diffraction characterization of enzyme bound MMT.  
Powder XRD of air dried Na-MMT complexes.  An increase in peaks 
representing basal layer spacing is observed from 1.0 nm in MMT only (black) 
to 4.0 nm with the addition of horseradish peroxidase (MMT-HRP, red), and 
1.8 nm and 4.9 nm with the addition of glucose oxidase (MMT-GOX, blue) due 
to intercalation of enzyme within the layers of stacked MMT. 
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B. MMT-HRP exhibits stabilized Michaelis-Menten kinetics. 
When analyzing activity of enzymes, kinetic values will give a detailed 
account of the reaction between an enzyme and its substrate.  As an enzyme 
population [E] binds with a substrate [S] it will form an intermediate complex [ES], 
which will form and break apart at equilibrium (at a rate of k1 and k-1).  From the 
enzyme-substrate complex a product [P] is formed at a rate of k2, and the 
enzyme returns to its previous state [E].  This can be summed by the following 
relationship: 
[ ]  [ ]
   
← 
  
→ [  ]
  
→ [ ]  [ ] 
The Michaelis-Menten kinetic parameter, Km, can be loosely defined as the ratio 
of the rate of dissociation to association of the enzyme-substrate complex, and is 
mathematically defined as: 
   
      
  
 
Other kinetic parameters include Vmax which indicates the maximum velocity at 
which product formation will occur, and kcat which indicates the turnover rate of 
product formation, and are related through the following: 
                 
where Etotal represents the total amount of enzyme (Michaelis and Menten).  
Kinetic values can be determined through a non-linearly fit curve as a result of 
the initial reaction velocity Vi versus substrate concentration [S] (Jones).  It is also 
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possible to graphically visualize the kinetic data using an extrapolation of one of 
several linear regressions, namely the Linweaver-Burke plot, Eadie-Hofstie plot, 
or the Hanes-Woolfe plot.   
Although the globular structure of HRP appears to be conserved when 
bound to MMT, there are many factors that will affect enzyme activity when 
bound versus free in solution.  Some studies have shown a decrease in activity 
of immobilized enzymes, while others show stabilization of activity due to 
molecular crowding (Lozzi et al.; Dunker and Fernandez).  We compared the 
enzyme activity of 100 ng of free versus MMT-immobilized HRP (enzyme 
concentration in MMT-HRP was estimated based on calculations as previously 
described).  Experiments were done in 100 mM monopotassium phosphate 
buffer at pH 9 and pH 4 using ABTS as a substrate for HRP.  The initial reaction 
velocity (Vi) of free and immobilized HRP reacted with H2O2 and increasing 
concentrations of ABTS substrate (S) is plotted in Figure 6 as a V versus S plot, 
and in Figure 7 as a Lineweaver-Burk plot, and all conditions result in a 
Michaelis-Menten kinetic profile.  While the activity of free HRP in solution is 
diminished at pH 4.5, the activity of MMT-HRP is stabilized to an extent which 
may occur through physical stabilization of the enzyme and protection from the 
harsh acidic environment, or through a buffering effect due to the inherent 
charged properties of MMT.  The associated kinetic (Vmax, Km, and Kcat) values 
were derived from the non-linear regression of the V vs S plot and are shown in 
Table 1.  From this data we can conclude that HRP immobilized on the surface of 
MMT in aqueous suspension will retain biological activity, and that the MMT itself 
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may act to protect the enzyme from the environment.  Using this system as a 
model, we predicted that EGF bound to MMT will also retain biological activity in 
an aqueous environment. 
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Figure 6.  MMT-HRP exhibits stabilized Michaelis-Menten kinetics at 
varying pH.  Free HRP and MMT-HRP kinetics upon reaction with ABTS 
substrate as described in materials and methods.  V versus S plots of each 
condition indicate Michaelis-Menten kinetics with full activity at pH 7, while 
HRP-MMT activity remains stabilized at pH 4.5. 
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Figure 7.  Lineweaver-Burke plot of the activity of free HRP versus MMT-
HRP.  The linear regression derived from the double reciprocal plot indicate a 
similar change in activity of free and MMT-bound HRP upon a shift in pH. 
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Table 1.  Enzyme kinetic values of free and MMT-immobilized HRP at pH 
7 and pH 4.5.  Quantification of enzyme kinetic parameters based on the 
Linweaver-Burke plot in figure 7. 
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 Km (mM) Vmax (mM) kcat (sec
-1) 
Free HRP pH 9 37.0 0.96 160.0 
MMT-HRP pH 9 8.5 0.31 51.7 
Free HRP pH 4 0.42 0.059 9.8 
MMT-HRP pH 4 0.17 0.13 21.7 
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C. MMT, kaolin, and halloysite inhibit keratinocyte and fibroblast 
proliferation in a dose dependent manner. 
To study the effect of MMT, kaolin, and halloysite on cell growth we 
cultured HaCaT cells in the presence of increasing concentration of MMT, kaolin, 
and halloysite.  Since it can be assumed that some biomolecular species within 
the culture media may bind to MMT, clay samples were pre-incubated in culture 
media, pelleted, and then added to the cells in a suspension of fresh media to 
mitigate the further removal of essential growth nutrients.  Cell growth was 
monitored for up to 48 hrs post-treatment using trypan-blue staining every 24 hrs.  
As shown in Figure 8, reduction in cell viability of HaCaT cells was observed 
when clay concentration exceeded 0.01 % in all cases.  A similar dose-
dependent decrease in cell viability has been observed in human hepatoma 
HepG2 cells upon exposure to Na-MMT, with clay treatments in excess of 50 
µg/ml (0.005 % w/v) inducing cell membrane damage due to reactive oxygen 
species generation (Lordan, Kennedy and Higginbotham; Dunker and 
Fernández).  However, HaCaT cells exhibit resilience at MMT concentration of 
0.001 %, resulting in no significant decrease in cell growth.  Therefore 
subsequent experiments were performed using 0.001 % MMT.  Since MMT was 
shown to have the best binding capacity to biomolecules such as HRP and GOX, 
MMT was used in all further experiments. 
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Figure 8.  Dose dependent survival of HaCaT and IMR-90 cells upon 
treatment with increasing clay concentrations.  HaCaT cells (2.5x105) or 
IMR-90 cells (5x104) were seeded in 6-well plates.  After 24 hr the media was 
replaced with DMEM containing increasing concentrations of MMT, halloysite 
(H), or kaolin (K).  Cells were harvested by trypsinization, subjected to live-
dead staining with trypan blue, and manually counted on a hemocytometer.  
Cells were counted before clay addition (0 hr), and at 24 and 48 hr post-
treatment. The y-axis represents the total number of cells.  Data shown is the 
average of three independent experiments. 
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 It is important to better understand the affect clay has on primary cells, 
which serve as a more accurate model of the in vivo system.  To do this, we 
cultured IMR-90 fibroblast cells in the presence of increasing concentrations of 
MMT.  An approximate 50 % reduction in cell viability with as little as 0.01 % 
MMT treatment was observed in IMR-90 cells as shown in Figure 9.  The 
sensitivity of IMR-90 cells to clays can be attributed in part to their primary nature.  
When observed visually, MMT particles can be seen to aggregate and adhere to 
the cell surface.  Figure 10A shows bright field images of IMR-90 cells untreated 
or treated with increasing doses of MMT.  Aggregates of MMT can be seen in 
contact with the cell membrane at MMT concentrations of 0.01 % and 0.05 %, 
and a coating of MMT on the cells and surrounding areas of the culture dish can 
be seen at a concentration of 0.1 %.  As aggregation occurs on the cell surface 
with increasing concentrations of MMT, the cells can be shown to clump and cell 
movement can be inhibited as shown by immunofluorescent images in Figure 
10B.  While untreated IMR90 cells (UT) exhibit extended, out-stretched 
morphologies, cells treated with MMT began to stick together and were inhibited 
from cell spreading.  Although clay adhesion to cell membranes in vitro exhibits 
such negative effects on proliferation and morphology at high concentrations, this 
property may be beneficial at lower concentrations in applications such as 
epidermal growth factor delivery.  Areas of wound healing during injury are very 
congested with biomolecules, including platelets, macrophages, enzymes, 
clotting factors, and many other molecules entering and exiting the area.   
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Figure 9.  Dose dependent survival of IMR-90 cells upon treatment with 
increasing clay concentrations.  IMR-90 cells (5x104) were seeded in 6-well 
plates, and treated with MMT as described above. 
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Figure 10.  MMT clay particles adhere to the surface of IMR-90 cells and 
cause aggregation.  A.  IMR-90 cells were plated in a six-well plate and at 24 
hr after seeding cells were treated with normal media, or media 
containing .01%, .05%, or 0.1% MMT for 24 hr.  Cells were washed 5X with 
sterile PBS, and imaged with bright field microscopy.  B.  IMR-90 cells were 
plated on sterilized coverslips in a six-well plate.  At 24 hr after seeding, cells 
were treated with media containing MMT for 24 hr before fixing and staining. 
Cells were fixed and stained for α-tubulin (botom) and DAPI was used to stain 
the nuclei (top) and imaged using fluorescence microscopy.  
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Adhesion directly to the cell membrane by MMT-EGF may prove advantageous 
for efficient delivery of growth factor to the healing cells. 
D. Characterization of MMT-EGF complexes. 
Since the previously described MMT-HRP model system suggested to us 
that MMT is a viable candidate clay for the delivery of EGF, we next sought to 
repeat the experimental procedures using EGF as the exchangeable biomolecule.  
Immunoblot analysis of MMT-EGF nanocomposite and supernatant using EGF-
specific antibodies was used to confirm the binding of MMT to EGF.  A 10 µl 
aliquot of 1 wt % MMT suspension (100 µg MMT) incubated with 50, 100, 250, or 
500 ng of reconstituted EGF in a final volume of 1 mL in dH2O was rotated for 12 
hr at 4 ˚C.  The MMT was pelleted and supernatant was collected after rotation to 
measure un-bound EGF.  As shown in Figure 11A, 1 mg MMT fully absorbs 250 
ng EGF with maximum binding occurring between 250-500 ng, as unbound EGF 
was only detected in the supernatant when EGF was in excess of 250 ng.  Since 
the cation exchange capacity (CEC) of Cloisite-Na® is known to be 92.6 
meq/100g clay, a loading concentration of 250 ng EGF per 1 mg MMT can be 
calculated to occupy 0.12 % of the available ion exchange sites on the MMT 
surface.  The remaining 99.9 % of the exchange sites continue to be occupied by 
Na+, which should allow Na-MMT to retain the ability to induce cationic activation 
of clotting factors.  From this data we selected a concentration of 250 ng EGF per 
1 mg MMT for subsequent experiments. 
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Figure 11.  Characterization of MMT-EGF nanocomplexes.  A. Immunoblot 
analysis of clay pellets and supernatants from 1 mg MMT incubated with 
increasing concentrations of EGF using anti-EGF antibodies.  The supernatant 
(sup) was collected to assay for un-bound EGF. EGF standards were also 
subject to immunoblot analysis as shown in the lower panel.  B.  Powder XRD 
of freeze-dried Na-MMT and MMT-EGF.  The peak at 2θ = 8.3 (001) indicates 
a basal layer spacing of approximately 1.1 nm, with no significant change in 
stacking of MMT upon the addition of EGF.   
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MMT-EGF was further characterized by powder XRD.  The diffraction 
intensity plotted against 2θ in Figure 11B resembles the typical diffraction pattern 
of Na-MMT.  The prominent peak at 2θ = 8.3 represent a characteristic 1.06 nm 
repeat distance of bare MMT crystallite sheet stacking, and reflects an 
approximate monolayer of H2O molecules hydrating the Na
+ cations within the 
gallery between the aluminosilicte layers.  Unlike intercalation of some 
biomolecules within MMT such as HRP which cause a uniform change in inter-
lattice spacing, addition of EGF to MMT does not lead to a distinct shift in repeat 
distance, indicating minimal to no intercalation (Lozzi et al.).  AFM analysis 
demonstrates that the binding of EGF molecules to MMT causes little to no 
change in the crystallite structure of MMT as shown in Figure 12.  A height 
increase of 1 nm can be seen in individual MMT sheets upon the addition of EGF 
and may be due to surface binding of EGF; however this has not been fully 
characterized. 
To measure the stability of MMT-EGF in cell culture media we incubated 
MMT-EGF suspensions in complete culture media at 37 ˚C and 5 % CO2 and 
analyzed the supernatant for EGF that had detached from the clay pellet up to 72 
hrs.  The starting materials are shown in Figure 13A with “media” representing 
the amount of EGF present in complete culture media itself, “10 ng EGF” as a 
reference point, and “MMT-EGF” as the amount of EGF in a fresh MMT-EGF 
pellet.  As shown in Figure 13B, a sample of MMT-EGF incubated at 37 ˚C and 5 
% CO2 for 72 hr was pelleted every 24 hr to collect the supernatant for analysis 
of detached EGF.  The MMT-EGF pellet was subject to immunoblot analysis for  
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Figure 12.  AFM analysis of MMT-EGF nanocomplexes.  Atomic force 
microscopy imaging of MMT (A-B) and MMT-EGF (D-E) with their 
corresponding height profiles (C and F).  10µl samples of MMT or MMT-EGF 
suspension were dried onto silicon wafers and imaged.  A height profile 
measured between the blue and red arrows indicate an increase of 
approximately 1 nm when EGF is bound to the surface.  Images displayed are 
representative of two independent experiments.  AFM experimentation and 
data analysis was carried out by Kristi Singh. 
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Figure 13.  MMT-EGF is stable in cell culture media.  A.  Immunoblot 
analysis of Epilife complete media, 10 ng EGF, and fraction of a control MMT-
EGF pellet.  B.  MMT-EGF was incubated at 37 ˚C and 5 % CO2; the sample 
was washed, pelleted, and the supernatant collected to assay for unbound 
EGF every 24 hr up to 72 hr.  C.  Three independent EGF-MMT samples were 
incubated at 37 ˚C and 5 % CO2 for 24, 48, and 72 hr; the sample was 
washed, pelleted, and the sup collected to assay for unbound EGF.  Fractions 
of all pellets and controls were resolved on a 15 % SDS-PAGE and probed 
with anti-EGF antibodies. 
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EGF that remained bound to MMT.  While much of the EGF remains in the MMT-
EGF complex, trace amounts of EGF can be observed in the supernatant at 48 
and 72 hr.  Figure 13C shows three separate pellets incubated in the same 
conditions for 24, 48, and 72 hr, with a single wash and supernatant collection at 
each of the aforementioned time points.  It can be seen that the MMT-EGF 
pellets remain intact and that no EGF is found in the supernatant, suggesting 
incubation and heating alone without periodic disturbance will not cause EGF to 
detach.  The fact that EGF is bound so tightly to the MMT surface via 
electrostatic forces questions whether or not EGFR on the cell membrane can 
access EGF upon MMT-EGF treatment.  It is known that EGFR consists of two 
inactive monomers that must bind two individual EGF ligands (or a potential EGF 
dimer) in order to autophosphorylate (Lu et al.).  Restriction of EGF movement 
while bound to MMT may provide a challenge for the receptor to accomplish this. 
E. Treatment of HaCaT cells with MMT-EGF leads to EGFR activation. 
After verification that a low dose of MMT alone was nontoxic and EGF was 
present in the composite material, we next sought to determine if the MMT-EGF 
complex was biologically active.  Upon ligand binding (EGF), EGF receptor 
(EGFR) forms a homodimer and autophosphorylates several tyrosine residues to 
form an active kinase.  Activation of EGFR sends a global signal promoting 
migration, growth and survival (Marques et al.).  In order to confirm activation of 
EGFR following MMT-EGF treatment of cells, we monitored EGFR activation 
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using phospho-specific antibodies to EGFR.  Treatment with MMT alone led to 
no phosphorylation of EGFR as expected (Figure 14A).  As shown in Figure 14B, 
treatment with either EGF or MMT-EGF led to phosphorylation of EGFR along 
the cell membrane as early as 30 min post-treatment. In a parallel experiment, 
full activation of EGFR by MMT-EGF was also observed at 120 min post-
treatment as measured by immunoblot analysis as seen in Figure 14C.  It 
remains unclear as to whether EGF is released from the clay surface or remains 
bound to MMT upon addition to cells, although results indicate minimal to no 
detectable detachment of EGF in culture media.  This leads us to the hypothesis 
that an intact MMT-EGF complex activates EGFR at the cell surface. 
Activated EGFR transmits a pro-growth signal to the cell through various 
signaling pathways, one major pathway being the phosphoinositide 3-kinase 
(PI3K)/AKT pathway (Dunker and Fernández).  To assess whether MMT-EGF 
nanocomposites function in a similar fashion as EGF alone, we monitored AKT 
phosphorylation and its downstream target GSK3β at multiple time points after 
addition of EGF or MMT-EGF to serum starved cells.  We observed that AKT 
activation occurs within 30 min in serum starved HaCaT cells treated with MMT-
EGF as shown in Figure 15, which mirrors the result of EGF treatment alone.  
AKT activation leads to phopshorylation of several downstream targets, such as 
GSK3β, to promote cell survival (Vander Haar et al.; Jope and Johnson).  We 
observed a conservative increase in GSK3β phosphorylation upon addition of 
MMT-EGF at time points consistent with, or slightly after, AKT  
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Figure 14.  Confocal microscopy analysis of EGFR activation.  A.  HaCaT 
cells were plated on sterilized coverslips.  At 24 hr post seeding, cells were 
subject to starvation with serum free DMEM for 24 hr, then fixed and stained 
for phospho-EGFR (green), and DAPI was used to stain the nuclei (blue) and 
imaged using confocal microscopy.  Cells with no treatment or MMT treatment 
alone show no EGFR activation.  Scale bar = 20 µm.  B.  Serum-starved 
HaCaT cells were maintained as described above and spiked with MMT-EGF 
or EGF for 30, 60, or 120 min before staining.  C.  In a parallel experiment, 
HaCaT cells were seeded and subject to starvation followed by EGF (5 ng/ml) 
or MMT-EGF (0.001 wt % MMT) treatment as previously described.  Whole 
cell lysates were subjected to immunoblot analysis using antibodies specific 
for phospho-EGFR or β-actin as a loading control. 
60 
 
 
61 
 
  
Figure 15.  Activation of EGFR leads to AKT and ERK activation in 
HaCaT cells treated with MMT-EGF.  HaCaT cells were serum starved for 24 
hr.  Cells were treated with 5 ng/mL EGF or 0.001 % MMT-EGF pre-
equilibrated in serum free DMEM, and whole cell extracts were obtained at 30, 
60, or 120 min. Whole cell lysates were subjected to immunoblot analysis for 
the indicated proteins.  β-actin was used as a loading control.   
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activation (Figure 15).  EGFR also promotes cell growth by means of the mitogen 
activated protein kinase (MAPK) pathways such as ERK1/2 via the RAS-RAF-
MEK cascade (Seger and Krebs).  Therefore we monitored ERK activation in 
HaCaT cells treated with MMT-EGF and demonstrated that ERK phosphorylation 
occurs within 30 min following treatment with MMT-EGF as shown in Figure 15.  
Altogether these results indicate MMT-immobilized EGF induces activation of 
EGFR and subsequent downstream protein signaling events at a similar rate to 
EGF treatment alone. 
F. MMT-EGF mediated increased cell migration of HaCaT is dependent on 
ERK activation. 
Since MMT is thought to interact with the cell membrane, we next sought 
to determine if the presence of MMT wound inhibit the normal migratory 
response of HaCaT cells to EGF (Lordan, Kennedy and Higginbotham).  
Keratinocyte motility during wound healing is known to be regulated by ERK 
activity via the RAS-RAF-MEK cascade (Matsubayashi et al.).  To monitor the 
effects of MMT-EGF on cell migration we performed in vitro scratch wound 
assays to determine cell migration across the “wound”.  Figure 16A shows that 
MMT-EGF treatment induced cell migration at a rate comparable to that of EGF 
treatment alone, while treatment with MMT alone fails to induce cell migration. 
Quantitation of the wound closure rates showed that although the MMT-EGF 
shows an initial lag, a complete wound closure comparable to EGF alone was 
observed by 24 hr (Figure 16B). Altogether our results demonstrate that EGF  
64 
 
  
Figure 16.  HaCaT migration in response to MMT-EGF treatment.   A. 
HaCaT cells were grown to near confluence and then serum starved for 24 hr.  
A scratch wound was induced and cells were left untreated (UT) in serum free 
media, or treated with 0.001 % MMT, 0.01 % MMT-EGF or 5 ng/ml EGF for up 
to 24 hr.  Images displayed are representative of three independent 
experiments.   Scale bar = 100 µm.  B. Quantification of scratch-wound 
closure is plotted as the average wound closure.  Error bars represent the 
standard deviation between experiments. 
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immobilized on the clay surface is active, can stimulate cell migration, and that 
the presence of MMT does not interfere with the cell movement.  A similar 
migratory response is observed in IMR-90 cells with MMT-EGF treatment as 
seen in Figure 17.  Although complete wound closure was not observed in either 
EGF or MMT-EGF treated cells, the cells responded to both EGF and MMT-EGF 
similarly. 
To verify the regulation of MMT-EGF induced cell migration by the ERK 
pathway, we performed scratch wound assays after pre-treatment with RAPA or 
PD98059 to inhibit activities of the mTOR and MEK1 pathaways, respectively 
(Kaufmann and Thiel).    The effectiveness of these inhibitors can be seen via 
Western Blot analysis as shown in Figure 18A.  RAPA inhibits the kinase activity 
of mTOR Complex 1, which can be observed by the effective decrease in 
phosphorylation of S6 by S6 kinase, a downstream target of mTOR.  PD98059 
selectively binds activation sites of MEK1 (ERK kinase), inhibiting its kinase 
activity as observed by the decrease in phosphorylated ERK.  As shown in 
Figure 18B, cells treated with RAPA displayed migration patterns similar to 
vehicle treated cells, suggesting that the activation of mTOR does not play a 
major role in MMT-EGF induced cell migration.  In contrast, cells treated with 
PD98059 resulted in no cell movement after MMT-EGF treatment, suggesting 
that the ERK1/2 pathway plays a major role in MMT-EGF induced cell migration 
during wound healing, consistent with the normal response of HaCaT cells to 
EGF. 
67 
 
  
Figure 17.  IMR-90 migration in response to MMT-EGF treatment.   A. 
IMR-90 cells were seeded in 6-well plates in DMEM containing 10 % FBS and 
grown to near confluence, then subjected to starvation with serum-free DMEM 
for 24 hr.  A scratch wound was induced and cells were left untreated (UT) in 
serum free media, or treated with .01 % MMT or MMT-EGF for up to 24 hr.  
Images displayed are representative of three independent experiments.   
Scale bar = 100 µm. 
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Figure 18.  Inhibition of MEK1 suppresses MMT-EGF induced cell 
migration.  A. HaCaT cells were grown to near confluence and then serum 
starved for 24 hr.  A scratch wound was induced and cells were pre-treated for 
4 hr with 100 nM rapamycin (RAPA) or 75 µM PD98059 in DMSO, or equal 
volumes of control vehicle, then left untreated (UT) in serum free media, or 
treated with 0.001 % MMT-EGF for up to 24 hr.  Scale bar = 100 µm.  B.  In a 
parallel experiment, HaCaT cells were serum starved for 24 hr.  Cells were 
pre-treated for 4 hr with 100 nM RAPA or 75 µM PD98059, then treated with 
5ng/mL EGF or 0.001 % MMT-EGF pre-equilibrated in serum free DMEM, and 
equivalent amounts of whole cell extracts were subjected to immunoblot 
analysis using antibodies specific for phospho-S6, total S6, phospho-ERK, 
and total ERK.  β-actin was used as a loading control. 
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We next examined the effects of MMT-EGF treatment on gene expression 
of THBS1, VEGF, and S100A shown to be involved in promoting cell growth in 
response to EGF treatment (Tong et al.; Stoll and Elder; Stoll, Zhao and Elder). 
The respective contribution of the mTOR and MEK1 pathways to gene induction 
was confirmed by treating cells with RAPA or PD98059 inhibitors prior to MMT-
EGF treatment. As shown in Figure 19 MMT-EGF treatment leads to increased 
gene expression of THBS1, VEGF, and S100A2.  Suppression of either the 
mTOR or MEK1 pathways by RAPA or PD98059, respectively, reduced MMT-
EGF mediated induction of THBS1 and VEGF.  Interestingly, MMT-EGF 
mediated upregulation of S100A2 expression was selectively blocked only by the 
MEK1 inhibitor PD98059 (Figure 19).  S100A2 encodes CaN19, a calcium-
binding protein involved in EGFR-triggered regenerative hyperplasia (Mischke et 
al.).  These results are indicative of the important roles that the MEK1-ERK 
pathway plays in MMT-EGF induced keratinocyte migration and gene induction, 
thereby confirming that the MMT-EGF complexes activate the normal 
proliferative and migration signaling components of HaCaT cells.  
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Figure 19.  Expression of S100A2, VEGF, and THBS1 in response to 
MMT-EGF treatment.  HaCaT were serum starved for 24 hr, then  pre-treated 
for 2 hr with 100 nM RAPA (R) or 75 µM PD98059 (PD), followed by treatment 
with 5 ng/mL EGF or 0.001% MMT-EGF (ME) pre-equilibrated in serum free 
DMEM.  At 1 hr post-treatment RNA was harvested, cDNA made and 
quantitative real time PCR was performed to quantify transcript levels of 
S100A2, VEGF, and THBS1.  Data is normalized to untreated cells (UT).  (*p 
< 0.01, **p < 0.001, ***p < 0.0001, relative to EGF or ME treated cells using 
student’s T-test).  Real-time qRT-PCR experimentation and data analysis was 
conducted by Katie Leonard. 
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IV. Discussion 
A.  Bio-inorganic hybrid nanomaterials and their applications. 
The field of polymer nanocomposites is a new and emerging technology 
that has already made a huge impact on material science.  Lamellar materials 
such as MMT have seen industrial use in composite materials that date back to 
the1980s, when Toyota began to use clay platelets as a filler in several materials, 
and noticed a significant increase in tensile strength, flexibility, modulus, and 
heat resistance with such low loading amounts of clay (5 %) (Zhu and Wilkie).  
The ability to improve both strength and toughness was previously impossible 
with conventional technologies, and because of this polymer nanocomposites 
gained much industrial attention in areas like enhancing barrier properties and 
fire retardancy.  More recently the study of natural and synthetic hybrid 
biomaterials has grown in the medical field with the development of implantations 
and prosthetics (Currie et al.).  Current efforts in biological-inorganic hybrid 
materials have been seen in tissue engineering scaffolds and drug delivery 
(Tsuru, Hayakawa and Osaka).  Porous silicate materials embedded with 
biological materials such as chitosan have been demonstrated to support cell 
growth and have become the centerpiece of many tissue engineering efforts.  
Understanding naturally occuring hybrid materials will aid in the development of 
constructing organic-inorganic hybrid materials ex vivo.  One such example of a 
biological hybrid material is bone, a combination of organic collagen fibers and 
inorganic hydroxyapatite crystals.  Understanding a system like the bone matrix 
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will improve the design of bio-inorganic materials, such as MMT-EGF as 
described in this study. 
 “Smart materials” are materials designed to physically or chemically 
respond to an environmental stimulus.  Engineered smart materials containing 
biologically active components like enzymes have been widely explored for 
applications such as biocatalysis, medical implantation, and electrochemical 
sensors (Ritchie; Forano and Prévot).  The use of glucose oxidase in the active 
layer of glucose sensors is a common example of exploiting the enzyme’s natural 
specificity for diagnostic applications (Fujii, Hill and Ariga).  Several challenges 
such as retention of biological activity and environmental stability necessitate the 
understanding of the interfacial interaction between the inorganic and biological 
material, in order to create a protective scaffold for the enzyme (Forano and 
Prévot).  Herein, we briefly discuss the intercalation of HRP and GOX between 
lamellar MMT platelets.  Preliminary results presented indicate a stabilization of 
HRP activity at a low pH that would normally render the enzyme inactive.  While 
this serves as an adequate proof-of-concept for applications such as the oral or 
topical delivery of biological-inorganic materials to an aqueous environment, it 
does not address some of the main challenges associated with the non-aqueous 
use of biological-inorganic materials.  However, the results presented within 
provide a foundation from which to build a more accurate model of protein-clay 
interfaces. 
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B.  Clay nanomaterials for drug delivery applications. 
 The drug binding-release properties of many nanomaterials have been 
well classified and prove to be a promising route for the delivery of many 
chemotherapeutic agents.  While not pursued fully in this study due to its weak 
interaction with EGF, halloysite nanotubular clay has been studied as a drug 
delivery vehicle in many research efforts both in vitro and in vitro (S. R. Levis and 
P. B. Deasy; Price, Gaber and Lvov; Lvov and Price).  As an inexpensive and 
widely abundant natural material, halloysite nanotubes provide an advantage 
over similarly structured materials like carbon nanotubes for applications 
requiring biocompatible nano-scale carriers, such as drug delivery.  Loading of 
the halloysite tubes with biomolecules usually includes solution mixing halloysite 
powder with the drug-containing solution, and decreasing the system’s pressure 
using vacuum chambers to draw the water out of the tubes (Lvov and Price).  
Although the release properties of drug-loaded halloysite systems have been 
fairly well characterized, we chose not to further pursue this material for EGF 
mediated wound healing. 
In this study we instead chose to develop MMT-EGF via ion exchange 
reaction, a procedure that does not require such equipment as vacuum 
chambers.  The mechanism of charged clay particles as drug carriers via 
electrostatic forces is idealized by Aguzzi et al. as a two-step ion exchange 
reaction, the first step being the “loading” of the clay via ion exchange of the drug 
molecule onto the clay surface, and the second being the “delivery” as the drug 
exchanges off for ionic species in the environment (Aguzzi et al.).  The release 
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mechanisms of drug-loaded MMT particles is observed with varying efficiencies 
and is dependent on the strength of the bond between MMT and the drug 
molecule, and the ionic conditions of the delivery environment.  In some cases 
complete unloading of the MMT particle is not achieved, and release efficiencies 
are lower than 50 %, while others observe a slow but complete release of all 
molecules (G. V. Joshi et al.; Ghanshyam V. Joshi et al.; Chen et al.).  Therefore 
it is accepted that in some cases, molecules will remain on the clay surface.  
While many drug-delivery studies focus on the release properties of clays, 
research groups using MMT in composite scaffolds recognize enhanced cell 
adhesion to clay-topped surfaces, and others analyzing MMT suspension in cell 
culture observe aggregation of clays onto the cell surface at high concentration 
with bright-field microscopy (Lordan, Kennedy and Higginbotham; Mehta et al.).  
This property may help draw MMT-EGF complexes to the cell membrane surface.  
In this study we have confirmed the binding of EGF to MMT via immunoblot 
analysis.  The low-loading concentration of our reaction conditions allow for the 
majority of ion-exchange sites to continue to be occupied by Na+, and results in 
little to no detectable intercalation of EGF within the interlayer space of dried 
MMT crystallite stacks.  Here we observe a strong bond between EGF and MMT 
after several days of incubation in complete media, suggesting that MMT-EGF 
remains largely intact while no detectable EGF is released into the environment.  
This leads to our hypothesis of a direct delivery of intact MMT-EGF complexes to 
the cell membrane that might be beneficial for wound healing. 
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C. Growth factor therapy for wound healing. 
The pros and cons of growth factor therapy for treating different types of 
wounds have been well reviewed (Hardwicke et al.). For example, Hardwicke et 
al. bring notice to the challenges associated with EGF treatment of chronic 
wounds, which include degradation by proteases of the protein upon treatment, 
and the need for protein modification or protective delivery systems to mitigate 
this response.  Montmorillonite has previously been shown to enhance the 
thermal and pH stability of immobilized enzymes, suggesting a degree of 
protection from the environment provided by the clay (Sanjay and Sugunan).  
While not explored in this study, immobilization of EGF on the surface of MMT 
may offer a similar degree of protection from an environment containing 
proteolytic enzymes, and warrants future study.  Several different delivery 
methods of EGF have been studied today, including electrospun nanofiber 
scaffolds conjugated with EGF for tissue repair of diabetic ulcers (Choi, Leong 
and Yoo).  EGF treatment is commonly administered to patients with diabetic 
ulcers in gel or ointment form.  Drawbacks of this treatment include a “burst” 
effect of EGF treatment, where EGF is consumed or destroyed soon after 
treatment, and frequent reapplication is necessary.  This is a challenge that the 
studies on EGF conjugated nanofibers attempts to address.  Another interesting 
study suggests that synthetic polymers found in artificial tears can activate EGFR 
and stimulate wound healing (Lozano et al.).  Findings like this may spur 
research in wound treatment using synthetic materials, which would be 
significantly cheaper than human growth factors.  Another reason to target EGFR 
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is for cancer therapies and imaging, since EGFR is overexpressed in many 
cancer cell lines (Zhang et al.).  Magnetic nanoparticles conjugated with EGF 
have been shown to be taken up by the cancer cell line CaCo-2, suggesting a 
possible means for site-directed magnetic imaging of tumors (Creixell et al.).  
While advances in nanoparticle imaging systems for tumors have gained much 
ground in recent years, challenges such as the cytotoxicity of such imaging 
agents still must be overcome (Selvan et al.).  Overall, EGFR is a powerful 
receptor, and understanding how to directly target EGFR will significantly impact 
the fields of wound healing, as well as the imaging and treatment of certain 
cancers. 
Battlefield injury provides a unique situation where growth factors may be 
used to enhance existing or newly discovered hemostatic agents.  Advanced 
cauterizing agents such as QuikClotTM work extremely well to prevent blood loss, 
but result in significant burns and inhibited long-term tissue regeneration (Arnaud 
et al.).  The battlefield wound first demands a rapid clotting ingredient, however 
as blood clotting treatments become more advanced and effective, long-term 
tissue regeneration also needs to be addressed.  This study focuses on MMT, a 
layered silicate shown to have natural hemostatic properties, as a carrier for 
tissue regenerating growth factors.  MMT-HRP was used as a model to verify the 
intercalation and retained biological activity of biomolecules on the surface of 
MMT.  We then confirm EGF will also bind to MMT, and have shown that MMT-
EGF will induce a signaling response in HaCaT cells, as summarized by Figure 
20, at the genetic, protein, and cellular level to stimulate cell migration.   
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Figure 20.  Schematic diagram of hypothesized MMT-EGF induced 
growth signaling in HaCaTs.  A schematic representation of the 
hypothesized signal transduction mechanism and cellular effects in HaCaT 
cells treated with 0.001 % MMT-EGF as observed in this study.  Tightly bound 
MMT-EGF complexes directly activate EGFR on the cell membrane, inducing 
activation of downstream signaling cascades leading to genetic upregulation 
and cell migration. 
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Confocal and immunoblot analysis confirm the successful activation of EGFR 
and subsequent signaling cascades following MMT-EGF treatment.  This 
activation mirrors the effect of EGF treatment alone, suggesting no negative 
alteration of EGFR activation in the presence of MMT.  Scratch wound assays 
confirm the ability of MMT-EGF to induce HaCaT cell migration, which is 
dependent on ERK activation, and also mirrors the normal activation pathway 
induced by EGF alone.  Finally, the upregulation of a subset of pro-growth genes 
can be observed in response to MMT-EGF, following the same trend as cells 
treated with EGF alone.  With EGF only occupying 0.01 % of the available Na+ 
exchange sites, the MMT-EGF complex is predicted to maintain its ability to 
activate clotting factors such as Factor XII.  Further investigation of the retained 
ability of EGF-bound MMT to induce coagulation is necessary.  A better 
understanding of the binding and release properties of MMT-EGF would help 
determine the potential use of silicate-growth factor composites as a wound 
healing treatment. 
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